Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, is known to reduce cardiovascular (CV) deaths and hospitalizations in patients with type 2 diabetes by promoting renal glucose excretion. However, the relative efficacy and safety of dapagliflozin are not known. This study aims to evaluate the safety and efficacy of dapagliflozin in reducing CV hospitalization and death.
This secondary analysis of randomized control trials included a total of 1,265 patients with type-2 diabetes and 5.199 patients with albuminuria. The participants were randomly assigned to receive dapagliflozin or placebo. The primary outcomes of the study were adverse cardiovascular events (such as myocardial infarction, stroke, or death) and the composite of CV death.
The findings suggested that patients in the placebo group had more CKD markers and high event rates at four years compared to patients in the intervention group. Estimates for risk reductions for the composite of CV death were similar across all subgroups. The risk difference for the composite of CV death was higher in patients with more CKD markers. Dapagliflozin lowered numerous amputations like diabetic ketoacidosis, hypoglycemic events, and fractures.
The research concluded that the effect of dapagliflozin on the relative risk of CV was consistent across patients with type-2 diabetes and albuminuria.
Ref: https://jamanetwork.com/journals/jamacardiology/article-abstract/2778552?resultClick=1
